Bladder Cancer – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Bladder Cancer – Pipeline Review, H2 2019’, provides an overview of the Bladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Bladder Cancer

– The report reviews pipeline therapeutics for Bladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bladder Cancer therapeutics and enlists all their major and minor projects

– The report assesses Bladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bladder Cancer”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“4D Pharma Plc

4SC AG

Aadi Bioscience Inc

AbbVie Inc

Abivax SA

Actuate Therapeutics Inc

ADC Therapeutics SA

Advaxis Inc

Agenus Inc

AIM ImmunoTech Inc

Alligator Bioscience AB

Alphamab Oncology

Altor Bioscience LLC

Amrita Therapeutics

Andes Biotechnologies

Apexian Pharmaceuticals Inc

APIM Therapeutics AS

Apollomics Inc

Aravive Inc

Archivel Farma SL

Arcus Biosciences Inc

Arisaph Pharmaceuticals Inc

Asieris Pharmaceuticals Co Ltd

AstraZeneca Plc

Aura Biosciences Inc

Aurigene Discovery Technologies Ltd

Aurora Oncology Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Neoantigen Biotechnology Co Ltd

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

BeyondSpring Inc

Bio-Thera Solutions Ltd

Biocad

Biohaven Pharmaceutical Holding Company Ltd

BioMed Valley Discoveries Inc

Biomics Biotechnologies Co Ltd

BioNTech SE

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Cantargia AB

Celgene Corp

CellCentric Ltd

Celldex Therapeutics Inc

Celon Pharma SA

Celprogen Inc

Celsion Corp

Celyad SA

CheckPoint Immunology Inc

CicloMed LLC

Cleveland BioLabs Inc

CMG Pharmaceutical Co Ltd

Cold Genesys Inc

Constellation Pharmaceuticals Inc

Convalife

Corvus Pharmaceuticals Inc

Cristal Therapeutics BV

CStone Pharmaceuticals Co Ltd

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

DelMar Pharmaceuticals Inc

Ectin Research AB

Eddingpharm Inc

Eisai Co Ltd

Elsalys Biotech SA

enGene Inc

EnGeneIC Ltd

EpiThany Inc

EpiVax Oncology Inc

Esperance Pharmaceuticals Inc

Evelo Biosciences Inc

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

F1 Oncology Inc

Fidia farmaceutici SpA

FKD Therapies Oy

For-Robin Inc

Forty Seven Inc

Gene Signal International SA

Genentech Inc

Genexine Inc

Genmab A/S

Genome & Co

Gilead Sciences Inc

GlaxoSmithKline Plc

GLG Pharma SA

H3 Biomedicine Inc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

HengRui YuanZheng Bio-Technology Co Ltd

Hope Biosciences Inc

Horizon Therapeutics PLC

I-Mab Biopharma Co Ltd

Immunocore Ltd

Immunomic Therapeutics Inc

ImmunSYS Inc

Immupharma Plc

Imugene Ltd

IMV Inc

Incanthera Ltd

Incyte Corp

Innovative Cellular Therapeutics Co Ltd

Innovent Biologics Inc

Iovance Biotherapeutics Inc

Johnson & Johnson

KLUS Pharma Inc

Komipharm International Co Ltd

Kyowa Kirin Co Ltd

Lipac Oncology LLC

LipoMedix Pharmaceutical Inc

LipoSeuticals Inc

Loxo Oncology Inc

Luye Pharma Group Ltd

Machavert Pharmaceuticals LLC

MacroGenics Inc

Manhattan Biosolutions LLC

MaxiVAX SA

Medivir AB

MedPacto Inc

MELEMA Pharma GmbH

Memgen LLC

Merck & Co Inc

Merck KGaA

Midissia Therapeutics Inc

Millennium Pharmaceuticals Inc

Modra Pharmaceuticals BV

Molecular Partners AG

Molecular Templates Inc

Moleculin Biotech LLC

Morvus Technology Ltd

MTG Biotherapeutics Inc

Mustang Bio Inc

NanoCarrier Co Ltd

Nanology LLC

NantKwest Inc

Nektar Therapeutics

Neon Therapeutics Inc

NeoTX Therapeutics Ltd

NGM Biopharmaceuticals Inc

Northwest Biotherapeutics Inc

Novartis AG

Ona Therapeutics SL

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Optimum Therapeutics LLC

Oxford BioTherapeutics Ltd

Peptron Inc

Pfizer Inc

Pharma Mar SA

Pieris Pharmaceuticals Inc

Plus Therapeutics Inc

Provecs Medical GmbH

PsiOxus Therapeutics Ltd

Puma Biotechnology Inc

Qu Biologics Inc

Ractigen Therapeutics Inc

Rainier Therapeutics Inc

Recursion Pharmaceuticals Inc

RemeGen Ltd

Replimune Ltd

Rexahn Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Savoy Pharmaceuticals Inc

Scholar Rock Inc

Seattle Genetics Inc

Serum Institute of India Ltd

Sesen Bio Inc

SetLance srl

Shandong Boan Biological Technology Co Ltd

Shionogi & Co Ltd

Sierra Oncology Inc

Sillajen Biotherapeutics

Sitka Biopharma Inc

Spectrum Pharmaceuticals Inc

Spring Bank Pharmaceuticals Inc

Stcube Inc

Syndax Pharmaceuticals Inc

Tara Immuno-Oncology Therapeutics LLC

Targovax ASA

Taris Biomedical LLC

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Tmunity Therapeutics Inc

Tocagen Inc

Tolero Pharmaceuticals Inc

Toray Industries Inc

Transgene SA

Treos Bio Ltd

UbiVac LLC

UroGen Pharmaceuticals Ltd

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxiion Therapeutics Inc

Viralytics Pty Ltd

Vivlmmune Inc

Vyriad Inc

Xbrane Biopharma AB

Xiangxue Life Sciences

Zhejiang Teruisi Pharmaceutical Inc

Zhejiang Yangshengtang Biotech Co Ltd

Zymeworks Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Bladder Cancer Overview 9

Bladder Cancer Therapeutics Development 10

Bladder Cancer Therapeutics Assessment 35

Bladder Cancer Companies Involved in Therapeutics Development 54

Bladder Cancer Drug Profiles 108

Bladder Cancer Dormant Projects 955

Bladder Cancer Discontinued Products 962

Bladder Cancer Product Development Milestones 964

Appendix 976

List of Tables

“List of Tables

Number of Products under Development for Bladder Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Route of Administration, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Bladder Cancer – Pipeline by 4D Pharma Plc, H2 2019

Bladder Cancer – Pipeline by 4SC AG, H2 2019

Bladder Cancer – Pipeline by Aadi Bioscience Inc, H2 2019

Bladder Cancer – Pipeline by AbbVie Inc, H2 2019

Bladder Cancer – Pipeline by Abivax SA, H2 2019

Bladder Cancer – Pipeline by Actuate Therapeutics Inc, H2 2019

Bladder Cancer – Pipeline by ADC Therapeutics SA, H2 2019

Bladder Cancer – Pipeline by Advaxis Inc, H2 2019

Bladder Cancer – Pipeline by Agenus Inc, H2 2019

Bladder Cancer – Pipeline by AIM ImmunoTech Inc, H2 2019

Bladder Cancer – Pipeline by Alligator Bioscience AB, H2 2019

Bladder Cancer – Pipeline by Alphamab Oncology, H2 2019

Bladder Cancer – Pipeline by Altor Bioscience LLC, H2 2019

Bladder Cancer – Pipeline by Amrita Therapeutics, H2 2019

Bladder Cancer – Pipeline by Andes Biotechnologies, H2 2019

Bladder Cancer – Pipeline by Apexian Pharmaceuticals Inc, H2 2019

Bladder Cancer – Pipeline by APIM Therapeutics AS, H2 2019

Bladder Cancer – Dormant Projects, H2 2019

Bladder Cancer – Discontinued Products, H2 2019

Bladder Cancer – Discontinued Products, H2 2019 (Contd..1), H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Bladder Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports